Comparison of the clinical effectiveness of nintedanib at full and reduced dosage in patients with idiopathic pulmonary fibrosis and progressive non-idiopathic fibrosis - Vienna 2024

Managing pulmonary fibrosis around the world

Chair(s): Nazia Chaudhuri, Tonia Magr

Session type: Poster session

Comparison of the clinical effectiveness of nintedanib at full and reduced dosage in patients with idiopathic pulmonary fibrosis and progressive non-idiopathic fibrosis

Paolo Cameli

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Idiopathic pulmonary fibrosis in hospitalized patients with lung cancer

Yujie Shi

Poster

Abstract

Familial Pulmonary Fibrosis in Two Referral Centers in Northeast of Brazil.

Fernanda De Aguiar Baptista

Abstract

Spectrum of disease and predictors of mortality in patients with idiopathic pulmonary fibrosis in South Africa

Muhammed Hoosen

Poster

Abstract

Familial Pulmonary Fibrosis: Clinical, genetic and radiological characterization

Mara Daniela Silva Sousa

Poster

Abstract

Prevalence and risk factors of progressive pulmonary fibrosis(PPF) in patients with Interstitial Lung Disease(ILD) in a tertiary care center in India

Devasahayam Jesudas Christopher

Poster

Abstract

IPF and lung cancer. Retrospective analysis of antifibrotic drugs and thoracic surgery.

Leonardo Gori

Poster

Abstract

Statin use and its implications on survival and disease progression in the European MultiPartner Idiopathic Pulmonary Fibrosis Registry (EMPIRE)

David Lang

Poster

Abstract

Changes in survival in people with IPF in England 20102020

Ann Morgan

Abstract

Effectiveness of pirfenidone in elderly patients with advanced functional impairment: a real-world study in idiopathic pulmonary fibrosis

Stefano Levra

Poster

Abstract

Prevalence and predictors of response to long-term treatment in patients with idiopathic pulmonary fibrosis (IPF).

Elisabetta Cocconcelli

Poster

Abstract

Role of 'dual Antifibrotic combination' Nintedanib plus Pirfenidone in Idiopathic Pulmonary Fibrosis: A favourable outcome & recommendation to change from monotherapy to combination regimen in a single center experience of 105 IPF cases

Shital Vishnu Patil

Poster

Abstract

The influence of symptoms on uptake of antifibrotic medication experience from a UK tertiary Interstitial Lung Disease (ILD) centre

Catherine Jennifer Rowan

Poster

Abstract

Comparison of the clinical effectiveness of nintedanib at full and reduced dosage in patients with idiopathic pulmonary fibrosis and progressive non-idiopathic fibrosis

Paolo Cameli

Poster

Abstract

Comparison of ILD at risk of PH between transplant center and referral care settings

Brenda Varela

Poster

Abstract

End-of-life of patients with idiopathic pulmonary fibrosis treated with antifibrotic therapy

Makiko Sato

Poster

Abstract

Quality of life in idiopathic pulmonary fibrosis in Latin American countries

Mart?n Eduardo Fern?ndez

Poster

Abstract

Idiopathic Pulmonary Fibrosis in the United Kingdom: Findings from the first decade of the largest single-country IPF Registry

Ahmed Fahim

Poster

Abstract

Disease trajectories in interstitial lung diseases Data from the EXCITING-ILD Registry

Katharina Buschulte

Poster

Abstract

The far reaching implications of Interstitial Lung Diseases Delayed Diagnosis

Radu Adrian Crisan-dabija

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}